Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Reitsamer, R; Peintinger, F; Prokop, E; Hitzl, W.
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Anticancer Drugs. 2005; 16(8): 867-870.
Doi: 10.1097/01.cad.0000173475.59616.b4
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Peintinger Florentia
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We conducted a prospective randomized study to compare the results of 3 cycles of epidoxorubicin/docetaxel to 6 cycles of epidoxorubicin/docetaxel prior to surgery in breast cancer patients with clinical stages II and III. Forty-five patients eligible for neoadjuvant chemotherapy were randomly assigned to receive either 3 (group 1) or 6 (group 2) cycles of epidoxorubicin/docetaxel prior to surgery. Chemotherapy consisted of epidoxorubicin 75 mg/m and docetaxel 75 mg/m on day 1 in 3-week cycles. The primary endpoint was the pathological complete response (pCR) rate; secondary endpoints were the rates of breast-conserving surgery and the axillary lymph node status in both groups. A pCR occurred in 10% (two of 20) in Group 1 and in 36% (nine of 25) in Group 2, which was statistically significant (p=0.045). Breast-conserving surgery could be performed in 70% (14 of 20) in Group 1 and in 76% (19 of 25) in Group 2 (p=0.065). Axillary lymph node status was negative in 45% (nine of 20) in Group 1 and 52% (13 of 25) in Group 2 (p=0.86). We conclude that 6 cycles of pre-operative epidoxorubicin/docetaxel versus 3 cycles of pre-operative epidoxorubicin/docetaxel significantly increases the pCR rates for breast cancer patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms - surgery
- Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - surgery
- Carcinoma, Lobular - drug therapy Carcinoma, Lobular - pathology Carcinoma, Lobular - surgery
- Chemotherapy, Adjuvant -
- Drug Administration Schedule -
- Epirubicin - administration & dosage Epirubicin - analogs & derivatives
- Female -
- Glucuronates - administration & dosage
- Granulocyte Colony-Stimulating Factor - administration & dosage
- Humans -
- Middle Aged -
- Neoadjuvant Therapy -
- Neoplasm Invasiveness - pathology
- Neoplasm Staging -
- Prospective Studies -
- Receptor, erbB-2 - metabolism
- Remission Induction -
- Taxoids - administration & dosage
- Treatment Outcome -
- Find related publications in this database (Keywords)
- breast cancer
- induction chemotherapy
- neoadjuvant chemotherapy
- pathological complete response rate
- pre-operative chemotherapy
- primary systemic therapy